Overview

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Status:
Terminated

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

This trial will compare the efficacy of sequential administration of Docetaxel, Carboplatin and Herceptin versus the administration of Vinorelbine and Herceptin combination as first line treatment in HER-2 positive patients with metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Hellenic Oncology Research Group

Collaborator:

University Hospital of Crete

Treatments:

Carboplatin
Docetaxel
Trastuzumab
Vinblastine
Vinorelbine